

DCS/AMAL/MD/24(F)/573/2016-17
October 13, 2016

The Company Secretary
SMS Pharmaceuticals Limited,
Plot No. 19 - III, Road No. 71,
Jubilee Hills (Opp. Bharatiya Vidya Bhavan Public School),
Hyderabad ,Telangana ,500096



Sir,

Sub: Observation letter regarding the Draft Scheme of Arrangement between SMS Pharmaceuticals Ltd and SMS Lifesciences India Ltd.

We are in receipt of Draft Scheme of Arrangement of SMS Pharmaceuticals Limited with SMS Lifesciences India Limited.

As required under SEBI Circular No. CIR/CFD/CMD/16/2015 dated November 30, 2015; SEBI vide its letter dated October 13, 2016 has inter alia given the following comment(s) on the draft scheme of arrangement:

- "Company shall duly comply with various provisions of the Circulars."

Accordingly, based on aforesaid comment offered by SEBI, the company is hereby advised:

- To duly comply with various provisions of the circulars.

In light of the above, we hereby advise that we have no adverse observations with limited reference to those matters having a bearing on listing/de-listing/continuous listing requirements within the provisions of Listing Agreement, so as to enable the company to file the scheme with Hon'ble High Court.

However, the listing of equity shares of SMS Lifesciences India Limited on the BSE Limited, shall be subject to SEBI granting relaxation under Rule 19(2)(b) of the Securities Contract (Regulation) Rules, 1957 and compliance with the requirements of SEBI circular. No. CIR/CFD/CMD/16/2015 dated November 30, 2015. Further, SMS Lifesciences India Ltd shall comply with SEBI Act, Rules, Regulations, directions of the SEBI and any other statutory authority and Rules, Byelaws, and Regulations of the Exchange.

The Company shall fulfill the Exchange's criteria for listing the securities of such company and also comply with other applicable statutory requirements. However, the listing of shares of SMS Lifesciences India Limited is at the discretion of the Exchange. In addition to the above, the listing of SMS Lifesciences India Limited pursuant to the Scheme of Arrangement shall be subject to SEBI approval and the Company satisfying the following conditions:

1. To submit the Information Memorandum containing all the information about SMS Lifesciences India Ltd in line with the disclosure requirements applicable for public issues with BSE, for making the same available to the public through the website of the Exchange. Further, the company is also advised to make the same available to the public through its website.

..... 2/-

2. To publish an advertisement in the newspapers containing all the information SMS Lifesciences Ltd in line with the details required as per the aforesaid SEBI circular no. CIR/CFD/CMD/16/2015 dated November 30, 2015. The advertisement should draw a specific reference to the aforesaid Information Memorandum available on the website of the company as well as BSE.
3. To disclose all the material information about SMS Lifesciences Ltd on a continuous basis so as to make the same public, in addition to the requirements if any, specified in Listing Agreement for disclosures about the subsidiaries.
4. The following provisions shall be incorporated in the scheme:
 - i. "The shares allotted pursuant to the Scheme shall remain frozen in the depository system till listing/trading permission is given by the designated stock exchange."
 - ii. "There shall be no change in the shareholding pattern of SMS Lifesciences Ltd between the record date and the listing which may affect the status of this approval."

Further you are also advised to bring the contents of this letter to the notice of your shareholders, all relevant authorities as deemed fit, and also in your application for approval of the scheme of arrangement.

Further, pursuant to the above SEBI circulars, upon sanction of the Scheme by the Hon'ble High Court, the listed company shall submit to the stock exchange the following:

- a) Copy of the High Court approved Scheme;
- b) Result of voting by shareholders for approving the Scheme;
- c) Statement explaining changes, if any, and reasons for such changes carried out in the Approved Scheme vis-à-vis the Draft Scheme;
- d) Copy of the observation letter issued by all the Stock Exchanges where Company is listed.
- e) Status of compliance with the Observation Letter/s of the stock exchanges;
- f) The application seeking exemption from Rule 19(2)(b) of SCRR, 1957, wherever applicable; and
- g) Complaints Report as per Annexure II of this Circular.
- h) Any other document/disclosure as informed by the Exchange.

The Exchange reserves its right to withdraw its 'No adverse observation' at any stage if the information submitted to the Exchange is found to be incomplete / incorrect / misleading / false or for any contravention of Rules, Bye-laws and Regulations of the Exchange, Listing Agreement, Guidelines/Regulations issued by statutory authorities.

Please note that the aforesaid observations does not preclude the Company from complying with any other requirements.

Yours faithfully,


Nitin Pujari
Manager



Assistant General Manager
Corporation Finance Department
Division of Issues and Listing-II
Phone: +91 22 2644 9447
Fax: +91 22 2644 9022. Email: sumank@sebi.gov.in

भारतीय प्रतिभूति
और विनिमय बोर्ड
Securities and Exchange
Board of India

CFD/DIL/NR/SK/OW/28399/2016
October 13, 2016

Shri. Nitin Pujari
Manager,
Bombay Stock Exchange Ltd.
Floor 25, PJ Towers, Dalal Street,
Mumbai - 400 001

Dear Sir,

Sub: Draft Scheme of Arrangement between SMS Pharmaceuticals Limited and SMS Lifesciences India Limited.

1. This has reference to your letter No. LIST/LO/SEBI/MD/171/2016-17 dated August 25, 2016, whereby you have forwarded the application of Draft Scheme of arrangement between SMS Pharmaceuticals Limited and SMS Lifesciences India Limited filed in accordance with SEBI Circular No. CIR/CFD/CMD/16/2015 dated November 30, 2016 (hereinafter referred to as 'the Circulars') for comments on the draft Scheme of Arrangement.
2. The matter has been examined by SEBI in the light of the provisions of the Circulars. Accordingly, SEBI's comments on the draft Scheme are as under
 - a. The stock exchange may ensure compliance with the said Circular.
 - b. The company shall duly comply with various provisions of the Circular.
3. Please note that the submission of documents/information in accordance with the Circulars to SEBI should not in any way be deemed or construed that the same has been cleared or approved by SEBI. SEBI does not take any responsibility either for the financial soundness of any scheme or for the correctness of the statements made or opinions expressed in the documents submitted.

Yours faithfully,


Sumank Kumar

CC:- : Mr. Kamlesh Patel
Manager,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot No. C/1, "G" Block
BKC, Bandra (E)
Mumbai - 400 051

सेबी भवन, प्लॉट सं. सी 4-ए, "जी" ब्लॉक, बांद्रा कुर्ला कॉम्प्लेक्स, बांद्रा (पूर्व), मुंबई - 400 051.
दूरभाष : 2644 9950 / 4045 9950 (आई.वी.आर. एस.), 2644 9000 / 4045 9000 फैक्स : 2644 9019 से 2644 9022 वेब : www.sebi.gov.in

SEBI Bhavan, Plot No. C4-A, "G" Block, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051.
Tel.: 2644 9950 / 4045 9950 (IVRS), 2644 9000 / 4045 9000 Fax : 2644 9019 to 2644 9022 Web : www.sebi.gov.in